A gold-standard FeNO diagnostics franchise with SaaS-like recurring consumables—now at a discount while US commercialization and COPD expansion play out.
Overview
NIOX Group Plc is a specialized global medtech focused exclusively on FeNO testing, a non-invasive breath-based biomarker that supports diagnosis and management of asthma and increasingly COPD by identifying Type‑2 airway inflammation. The company’s competitive identity is “gold standard” positioning: NIOX devices are the only FeNO systems in the US and EU fully conforming to ATS/ERS performance standards, and they benefit from an extensive evidence base (6,000+ studies) that reinforces clinical and research adoption. The business model is highly recurring: clinical sites buy devices (notably NIOX VERO, with NIOX PRO newly introduced) but the economic engine is consumables—sensors and disposables—driving repeat purchases and high revenue visibility, with consumables consistently comprising over 90% of clinical segment revenue. NIOX serves two segments: Clinical (hospitals and primary care) and Research (pharma/CRO clinical trials). FY2025 results showed meaningful acceleration: total revenue reached £48.7m (+17%), with clinical revenue £38.6m (+7%) supported by installed base growth, and research revenue £10.1m (+77%) driven by unexpectedly strong COPD-related trial activity. Profitability rose with operating leverage: adjusted EBITDA was £16.7m (+21%) and margin 34%, while cash increased to £19.9m and the balance sheet remains debt-free. The investment appeal centers on a durable recurring consumables annuity, guideline-driven expansion into primary care, and an emerging COPD opportunity—balanced against execution risk in the US direct-sales buildout, policy/price risk in China, reimbursement sensitivity, and the strategic concentration of being effectively a one-biomarker company.